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Neuro-Sweet disease mimicking recurrent anaplastic astrocytoma 
associated with therapy-related myelodysplastic syndrome: A case report 
  
Introduction 
Sweet's syndrome (SS), an acute febrile neutrophilic dermatosis, is 
characterized by fever, neutrophilia, tender erythematous skin lesions (papules, 
nodules, and plaques), and a diffuse infiltrate predominantly composed of mature 
neutrophils. Neuro-Sweet disease (NSD) is an extracutaneous manifestation of 
SS [1]. SS can also present as a paraneoplastic syndrome, which is a 
malignancy-associated form of the condition that is most commonly related to 
acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).  
Therapy-related myelodysplastic syndrome (t-MDS) is rare but one of 
the most lethal complications of alkylating agents such as temozolomide (TMZ) 
and ACNU [2], which are widely used for adjuvant chemotherapy with or without 
radiotherapy for malignant glioma. In this study, we provide the first report of NSD 
mimicking the recurrence of anaplastic astrocytoma (AA), which was 




In July 2004, a previously healthy 52-year-old man presented with focal 
seizure. Magnetic resonance (MR¬) imaging of the brain showed a lesion in the 
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right frontal lobe (Fig. 1A). A gross total resection was performed, and the 
pathology was found to be consistent with AA. Postoperative regional 
radiotherapy with 40 Gy was administered over 4 weeks, followed by 15 cycles of 
chemotherapy with ACNU at an initial dose of 80 mg and an extended dose of 
138 mg from the ninth to the fifteenth course. In August 2007, however, 
chemotherapy was discontinued because of leukocytopenia. Despite the 
administration of granulocyte colony-stimulating factor (G-CSF), his hematologic 
findings did not normalize. In January 2008, bone marrow aspiration and biopsy 
were performed, which showed a hypocellular marrow with moderate fibrosis and 
dysplasia. There was no increase in the bone marrow blasts, which constituted 
<5% of the nucleated cells. These findings were found to be consistent with 
t-MDS according to the WHO classification. Despite ACNU withdrawal, AA did 
not recurred (Fig. 1B).  
 
Second presentation 
In June 2010, he was admitted to our hospital because of painful 
erythema on the extremities and intractable focal seizure of the left hand. On 
admission, his skin lesions were purple-red, nonpruritic, and tender and 
measured 1–2 cm in diameter (Fig. 2A). MR imaging showed hyperintensity on 
FLAIR at the periphery of the resected cavity. The margin of the tumor resection 
cavity was enhanced by contrast medium (Fig. 1C). At the time, we suspected the 
recurrence of AA. However, an intractable fever over 38.5°C, which was resistant 
to antibiotics, appeared. Hematological examination showed a white blood cell 
count of 1.63 × 109/L (of which, 0.87 × 109/L were neutrophils); however, 
erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were within 
normal limits. Skin biopsy showed deep dermal infiltration of mature neutrophils, 
spared epidermis, and absence of vasculitis, strongly suggesting SS (Fig. 2B). 
On the seventh hospital day, treatment with oral prednisolone (20 mg/day x 5 
days) was initiated, and the fever was rapidly alleviated. However, on the 13th 
hospital day, a fever of over 39°C recurred. Furthermore, consciousness 
disturbance, focal seizure, left hemiparesis, and neck stiffness appeared. MR 
imaging showed enlargement of the FLAIR hyperintensity surrounding the cavity 
(Fig. 1D). Cerebrospinal fluid   (CSF)   analysis   showed  3720   cells/μL   (of  which,  
36% were neutrophils), 262 mg/dL protein, 47 mg/dL glucose; moreover, CSF 
cultures were negative in 2 samples tested separately. Because fever and 
neurological symptoms did not improve for 2 days despite an intensive 
carbapenem antibiotic treatment (6 g/day), we suspected that his meningitis must 
have been caused by NSD. On the 16th hospital day, he was treated with 
intravenous methylprednisolone (1 g/day for 3 days), followed by oral 
prednisolone treatment (50 mg/day). Thereafter, his clinical symptoms and 
abnormal MR findings improved (Fig. 1E), indicating a dramatic response to 
steroid pulse therapy.   
 
Discussion  
Various neurological manifestations of NSD have been reported, such 
as benign encephalitis, aseptic meningitis, polyneuropathy, and psychiatric 
symptoms [1]. Clinical diagnostic criteria for NSD were proposed by Hisanaga et 
al. in 2005. The 3 main features of NSD patients have been described. First, NSD 
patients have neurological features that are highly responsive to systemic 
glucocorticoid treatment; however, they frequently experience recurrent 
encephalitis or meningitis, which are usually accompanied with fever of over 
38°C. The second feature is dermatologic, in that the patients develop painful or 
tender, dull red erythematous plaques or nodules with predominantly neutrophilic 
infiltration of the dermis and spared epidermis without leukocytoclastic vasculitis. 
The third feature is the absence of cutaneous vasculitis, thrombosis, and typical 
uveitis, which are seen in Behçet's disease [3]. Because our patient exhibited all 
the 3 features, he was diagnosed as having NSD. However, HLA-B54, which is 
associated with SS [3], was not detected in our patient, suggesting that the 
pathogenic mechanism of NSD in our patient might be unusual.  
SS presents in 3 clinical settings: classical (or idiopathic), 
malignancy-associated, and drug-induced. Twenty-one percent of patients with 
SS either have a solid tumor or a hematologic malignancy, as that observed in 
our patient [1]. Malignancy-associated SS is most commonly related to 
hematologic malignancy, especially AML and MDS [4]. The nature of the 
relationship between these dermatoses and the underlying hematologic 
malignancy is unknown. However, it is known that the infiltrate is mostly 
composed of mature neutrophils even when the patient's blood or bone marrow 
contains few mature neutrophils, as observed in the present case [4]. This finding 
had lead many authors to conclude that neutrophilic infiltrates in the skin of these 
patients  are  “nonspecific”  inflammatory  processes  [4].    
In the pre-TMZ era, nitrosoureas constituted the primary alkylator-based 
chemotherapy for the treatment of malignant gliomas. t-MDS/AML have been 
described as life-threatening complications following therapy of primary brain 
tumors with classic alkylating agents such as nitrosoureas or procarbazine, RT 
alone, or combined chemotherapy and RT [2]. Therapy-related myeloid 
neoplasms account for approximately 20% of all cases of myeloproliferative 
neoplasms. The incidence among patients treated with cytotoxic agents varies 
according to the underlying disease, specific agents, time of exposure, and dose.  
The pathogenesis of SS is unknown. It is currently thought that cytokine 
dysregulation accounts for most of the clinical, pathological, and laboratory 
changes seen in SS; the cytokines include interleukin (IL)-1, IL-3, IL-6, IL-8, 
G-CSF,  and  interferon  γ  [1].  Vergaraet  al.  reported  that  previously  irradiated  skin  
may behave as a locus minoris resistentiae (a place of less resistance) that 
favors the localization of SS lesions [5]. Not only irradiation but also epidermal 
damage caused by mechanical, surgical, chemical, or solar stimuli can directly 
promote cutaneous lesions or result in a common etiology such as injury to the 
dermal connective tissue, which subsequently contributes to the development of 
skin lesions [1]. However, development of NSD in the irradiated brain after glioma 
resection has not yet been reported. Interestingly, a hyperintensity lesion on 
FLAIR was observed only within the irradiated field (Fig. 1D). Expression of 
various immunoregulatory molecules such as IL-1, IL-6, TNF-α,  and  NF-kB are 
affected due to delayed responses as a result of brain irradiation. These findings 
lead us to speculate that brain irradiation after surgical resection increases the 
risk of NSD development.  
  
Conclusion 
It was difficult to distinguish NSD from AA until the brain lesions 
dramatically disappeared after glucocorticoid administration. In this case, t-MDS, 
a lethal complication of alkylating agent chemotherapy, played an important role 
in NSD pathogenesis; moreover, brain irradiation may influence the location of 




1. Cohen PR. Sweet's syndrome - a comprehensive review of an acute 
febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34. 
2. Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, 
Henson JW. Treatment-related myelodysplasia/AML in a patient with a history of 
breast cancer and an oligodendroglioma treated with temozolomide: case study 
and review of the literature. Neuro Oncol 2006;8:280-283. 
3. Hisanaga K, Iwasaki Y, Itoyama Y. Neuro-Sweet disease: clinical 
manifestations and criteria for diagnosis. Neurology 2005;64:1756-1761. 
4. Tomasini C, Aloi F, Osella-Abate S, Dapavo P, Pippione M. Immature 
myeloid precursors in chronic neutrophilic dermatosis associated with 
myelodysplastic syndrome. Am J Dermatopathol 2000;22:429-433. 
5. Vergara G, Vargas-Machuca I, Pastor MA, Farina MC, Martin L, 
Requena L. Localization of Sweet's syndrome in radiation-induced locus minoris 






Gadolinium-enhanced axial T1 weighted images (upper panel) and axial FLAIR 
images (lower panel) are shown. In 2004 July, heterogeneous enhanced lesion in 
right frontal lobe was detected (A). Gross total resection was achieved (B), 
followed by regional radiotherapy and ACNU-based chemotherapy. Histological 
examination revealed AA. In 2010 June, the margin of the tumor resection cavity 
became enhanced by contrast medium and FLAIR hyper-intensity lesion was 
detected (C). After two weeks, FLAIR hyper-intensity lesion markedly expanded 
during neurological deterioration (D). White square indicates the range formerly 
irradiated. Note that FLAIR hyper-intensity lesion was not seen outside of 
irradiated field. After the treatment with glucocorticoid, MR findings were 
improved dramatically (E).      
 
Figure 2 
Cutaneous lesion of lower leg (dorsal). Erythematous eruption was observed (A). 
Hematoxylin-Eosin staining of cutaneous lesion showed dense infiltration of 






(1) We report a case of neuro-Sweet disease (NSD) mimicking the recurrence of 
anaplastic astrocytoma (AA), which was accompanied by therapy-related 
myelodysplastic syndrome (t-MDS) after ACNU-based chemo-radiotherapy AA.  
(2) It was difficult to distinguish NSD from AA until the brain lesions dramatically 
disappeared after glucocorticoid administration. In this case, t-MDS, a lethal 
complication of alkylating agent chemotherapy, played an important role in NSD 
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